Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma.
- Author:
Ying-Zi YANG
1
,
2
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cyclophosphamide; therapeutic use; Doxorubicin; therapeutic use; Etoposide; therapeutic use; Humans; Lactate Dehydrogenases; metabolism; Lymphoma, B-Cell; drug therapy; Neoplasm Recurrence, Local; Prednisone; therapeutic use; Survival Rate; Thalidomide; therapeutic use; Treatment Outcome; Vascular Endothelial Growth Factor A; blood; Vincristine; therapeutic use
- From: Journal of Experimental Hematology 2016;24(1):84-88
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma.
METHODSEighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared.
RESULTSThe clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHOPE+thalidomide group was significant longer than that in CHOPE group alone (P < 0.05). The incidence of III-IV degree toxic side effects was not significantly different between 2 these groups (P > 0.05).
CONCLUSIONCompared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects.
